The single antibody treatment works by blocking the protein's signal, thus instructing the body's immune system to attack the cancer cells.
"What we've shown is that CD47 isn't just important on leukemias and lymphomas," Stanford Professor of Pathology and lead study author Dr. Irving Weissman told Science NOW, referring to his previous research that inspired the most recent study. "It's on every single human primary tumor that we tested."
Join us on our
Share this page with your friends
on your favorite social network: